ATS 2019 Virtual Final Program

217 Inhaled PLGA Particles of Spermine Nonoate, Nitric Oxide Donor, as a Promising Targeted Therapy to Reduce Pulmonary Arterial Pressure in PAH/ A. Alobaida, F. Ahsan, Amarillo, TX, p.A4406 218 Female Sex Hormones Can Prevent but Not Reverse Established Pulmonary Arterial Hypertension in the SU5416/Chronic Hypoxia Model/ K.R. Chaudhary, Y. Deng, A. Yang, K. Rowe, D.J. Stewart, Ottawa, Canada, p.A4407 219 Dysregulated Wnt/ca2+ Signaling Is Associated with Pericyte Hypercontractility and Proliferation in PAH/ A. Nathan, J. Acosta Uribe, A. Chakraborty, K. Yuan, E. Shamskhou, K. Suresh, L.A. Shimoda, V. De Jesus Perez, Palo Alto, CA, p.A4408 220 ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models Is Active in Patients with Severe Pulmonary Arterial Hypertension/ M. Simon, M. Gomberg-Maitland, R.J. Oudiz, R.F. Machado, F.P. Rischard, J.M. Elinoff, B. Grigorian, A. Schmid, S. Hou, N.P. Desai, M.T. Gladwin, Pittsburgh, PA, p.A4409 221 CCR2- and CCR5-Mediated Crosstalk Between Macrophages and Pulmonary-Artery Smooth Muscle Cells Drives Pulmonary Hypertension/ S. Abid, E. Marcos, A. Parpaleix, V. Amsellem, M. Breau, A. Houssaini, N. Vienney, P. Validire, M. Lefevre, G. Derumeaux, S.M. Evans, C. Hubeau, M. Delcroix, R. Quarck, S. Adnot, L. Lipskaia, Creteil, France, p.A4410 222 Msx1 Overexpression in Mouse Lung Leads to Loss of Small Pulmonary Vessels/ M. Talati, X. Chen, S. Shay, S. Gladson, J. Penn, J.D. West, Nashville, TN, p.A4411 223 Targeting HIF-2a for the Treatment of Pulmonary Arterial Hypertension/ Z. Dai, M.M. Zhu, Y. Peng, N. Machireddy, C. Evans, R.F. Machado, X. Zhang, Y. Zhao, Chicago, IL, p.A4412 224 Targeting Pathologic Hyaluronan Synthesis in Pulmonary Hypertension/ V. Tseng, J. Klienhenz, T. Murphy, E.N. Grayck, C.M. Hart, Atlanta, GA, p.A4413 CLINICAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION C27 TB TREATMENT 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Four (Level 2) Abstract Summaries 9:15-9:45 Viewing/Discussion 9:45-11:15 Chairing: S.H. Kasperbauer, MD, Denver, CO M.C.I. Lipman, MD, London, United Kingdom 301 Treatment Outcome of Tuberculosis Patients in a Directly Observed Treatment Shortcourse (DOTS) Referral Centre in Delta State, Nigeria: A Five Year Review (2012 - 2016)/ N.S. Awunor, I. Alenoghena, A. Akpodiete, Abraka, Nigeria, p.A4414 302 Factors Associated with High Mortality During TB Treatment in New Mexico: 2007-2017/ R. Patel, A. Makaretz, D. Fortune, N. Villalobos, S.R. Rosenthal, R. Bramble, M. Burgos, E.J. Carter, Providence, RI, p.A4415 303 Study of First Line Anti Tuberculosis Drugs’ Sensitivity Testing in Newly Diagnosed Sputum Smear Positive Category-I and Category-II Patients and Their Treatment Outcome/ D. Gandhi, S. Patel, R. Jiyani, Jamnagar, India, p.A4416 304 Outcomes of Extended Duration Therapy for Drug-Susceptible Cavitary Pulmonary Tuberculosis/ H. Choi, H. Lee, Y. Sim, T.R. Shin, D.-G. Kim, Seoul, Korea, Republic of, p.A4417 305 Treatment Outcomes of Tuberculous Meningitis in Adults: A Systematic Review and Meta-Analysis/ M. Wang, J.-Q. He, Chengdu, China, p.A4418 306 Changes in Body Weight According to Smear Positive or Negative Before and After Anti-Tuberculosis Treatment/ Y. Ko, Y.I. Hwang, Seoul, Korea, Republic of, p.A4419 307 Genetic Heteroresistance and Associated Phenotypic Resistance in Patients Newly Diagnosed with Drug Resistant-Tuberculosis in KwaZulu-Natal, South Africa/ C. Nimmo, J. Millard, K. Brien, M.R. O’Donnell, A. Grant, J. Breuer, F. Balloux, A.S. Pym, London, United Kingdom, p.A4420 308 Pilot Study Evaluating Challenges of Video Based Directly Observed Therapy for Ultra-Short Course Treatment of Latent Tuberculosis Infection in New Orleans, Louisiana/ M. Light, J. Ali, N. Lapinel, New Orleans, LA, p.A4421 309 Treatment Outcomes for Multidrug Resistant Tuberculosis at a Tertiary Hospital in South Korea from 2005 to 2017/ S.H. Yong, E.H. Lee, A.Y. Leem, S.H. Lee, S.Y. Kim, K.S. Chung, J.Y. Jung, M.S. Park, Y.S. Kim, J. Jang, Y.A. Kang, Seoul, Korea, Republic of, p.A4422 310 Treatment of Musculoskeletal Tuberculosis Over 10 Years in North London: A Retrospective Audit/ T.P.W. Jones, A.S. Jhass, D. Creer, M.C.I. Lipman, I.M. Cropley, London, United Kingdom, p.A4423 311 Effect of Diabetes Mellitus on Treatment Outcomes and Side Effects in Drug-Resistant Pulmonary Tuberculosis Patients Receiving DR-TB Regimens in Dr. Soetomo Hospital. A Retrospective Study/ S. Soedarsono, Surabaya, Indonesia, p.A4424 312 Selective HDAC3 Inhibitor Restricts Mycobacterial Growth and Modulates Macrophage Immune Responses/ M. Campo-Patino, S. Heater, J. Simmons, G.J. Peterson, C.M. Stein, H. Mayanja-Kizza, W.H. Boom, T.R. Hawn, Seattle, WA, p.A4425 313 Targeting PD-1 Rescues Protective T Cell Response to Facilitate Bacillary Clearance and Modulation of the Efflux Pump Expression of Mycobacterium Tuberculosis/ D. Mitra, S. Chakraborty, New Delhi, India, p.A4426 314 Isoniazid as an Immunomodulatory Agent for Latent Tuberculosis Infection Treatment in View of Invariant Natural Killer T (iNKT Cells/ W.-J. Su, S.-F. Huang, J.-Y. Feng, Y.-Y. Yang, Taipei, Taiwan, p.A4427 ATS 2019 • Dallas, TX 236 TUESDAY • MAY 21